Mesothelioma

Exposure to Asbestos With BAP1 Mutation Increases Risk of Mesothelioma

In a study presented today at the American Association for Cancer Research Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that mice with a BAP1 germline mutation, after exposure to small levels of asbestos, had a greater chance of developing malignant mesothelioma. The study is being published in[…]

Read More »

Exercise to Boost Immunity in Advanced Cancer (BICEP)

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

Read More »

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

Read More »

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).

Read More »

ADI-PEG20 Improves Survival in Mesothelioma Patients

ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]

Read More »

Breath Test Could Improve Diagnosis of Mesothelioma

A new way to diagnose mesothelioma may have been discovered. Researchers have found that the exhaled breath of patients could have the potential to be a screening tool for malignant pleural mesothelioma. The information was presented at the International Association for the Study of Lung Cancer 2023 World Conference on[…]

Read More »

Occupational and Environmental Exposure to Asbestos Reduces Longevity in Patients

Mesothelioma is a hard cancer to treat that is mainly caused by asbestos. People with this cancer typically do not live very long after diagnosis, but some people live longer than expected. A study recently published in the journal Toxics looked at people with mesothelioma and asbestos-caused lung cancer. All[…]

Read More »

Altered CAR-T Cell Therapy for the Treatment of Mesothelioma

Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]

Read More »

GPC3/​Mesothelin-CAR-γδT Cells Against Cancers

Primary Outcome Measures Number of Patients with Dose Limiting Toxicity A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the γδT cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. Secondary Outcome Measures Percent of Patients with best[…]

Read More »